image
Healthcare - Medical - Devices - NASDAQ - US
$ 11.97
0.504 %
$ 357 M
Market Cap
-12.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NPCE stock under the worst case scenario is HIDDEN Compared to the current market price of 12 USD, NeuroPace, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NPCE stock under the base case scenario is HIDDEN Compared to the current market price of 12 USD, NeuroPace, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NPCE stock under the best case scenario is HIDDEN Compared to the current market price of 12 USD, NeuroPace, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
65.4 M REVENUE
43.72%
-27.2 M OPERATING INCOME
33.39%
-33 M NET INCOME
30.00%
-19.7 M OPERATING CASH FLOW
46.56%
23 M INVESTING CASH FLOW
-3.24%
8.13 M FINANCING CASH FLOW
1558.57%
21.1 M REVENUE
9.37%
-4.24 M OPERATING INCOME
31.89%
-5.45 M NET INCOME
27.44%
-1.72 M OPERATING CASH FLOW
55.79%
1.4 M INVESTING CASH FLOW
-56.75%
2.9 M FINANCING CASH FLOW
469.35%
Balance Sheet NeuroPace, Inc.
image
Current Assets 92.7 M
Cash & Short-Term Investments 66.5 M
Receivables 12.3 M
Other Current Assets 14 M
Non-Current Assets 14.9 M
Long-Term Investments 0
PP&E 14.4 M
Other Non-Current Assets 524 K
Current Liabilities 16.2 M
Accounts Payable 2.33 M
Short-Term Debt 1.63 M
Other Current Liabilities 12.3 M
Non-Current Liabilities 70.8 M
Long-Term Debt 70.8 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall NeuroPace, Inc.
image
Revenue 65.4 M
Cost Of Revenue 17.3 M
Gross Profit 48.1 M
Operating Expenses 75.3 M
Operating Income -27.2 M
Other Expenses 5.78 M
Net Income -33 M
RATIOS
73.56% GROSS MARGIN
73.56%
-41.54% OPERATING MARGIN
-41.54%
-50.38% NET MARGIN
-50.38%
-159.56% ROE
-159.56%
-30.61% ROA
-30.61%
-35.01% ROIC
-35.01%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NeuroPace, Inc.
image
Net Income -33 M
Depreciation & Amortization 1.6 M
Capital Expenditures -173 K
Stock-Based Compensation 9.56 M
Change in Working Capital -2.48 M
Others 8.4 M
Free Cash Flow -19.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NeuroPace, Inc.
image
Wall Street analysts predict an average 1-year price target for NPCE of $18.3 , with forecasts ranging from a low of $15 to a high of $20 .
NPCE Lowest Price Target Wall Street Target
15 USD 25.31%
NPCE Average Price Target Wall Street Target
18.3 USD 53.16%
NPCE Highest Price Target Wall Street Target
20 USD 67.08%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership NeuroPace, Inc.
image
Sold
0-3 MONTHS
1.27 M USD 1
3-6 MONTHS
609 K USD 1
6-9 MONTHS
1.59 M USD 1
9-12 MONTHS
7.51 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Oct 23, 2024
Sell 885 USD
KCK LTD.
10 percent owner
- 147
6.02 USD
2 months ago
Oct 25, 2024
Sell 1.22 M USD
KCK LTD.
10 percent owner
- 223991
5.4513 USD
2 months ago
Oct 22, 2024
Sell 24.9 K USD
KCK LTD.
10 percent owner
- 4082
6.0885 USD
3 months ago
Oct 18, 2024
Sell 30.7 K USD
KCK LTD.
10 percent owner
- 4878
6.2919 USD
2 months ago
Oct 21, 2024
Sell 22.7 K USD
KCK LTD.
10 percent owner
- 3720
6.0964 USD
3 months ago
Oct 03, 2024
Sell 23.1 K USD
KCK LTD.
10 percent owner
- 3318
6.9665 USD
3 months ago
Oct 04, 2024
Sell 39.8 K USD
KCK LTD.
10 percent owner
- 5757
6.9185 USD
3 months ago
Oct 07, 2024
Sell 32.7 K USD
KCK LTD.
10 percent owner
- 4910
6.6573 USD
3 months ago
Oct 08, 2024
Sell 38.6 K USD
KCK LTD.
10 percent owner
- 6000
6.4253 USD
3 months ago
Oct 09, 2024
Sell 19.1 K USD
KCK LTD.
10 percent owner
- 3123
6.1048 USD
3 months ago
Oct 10, 2024
Sell 15.3 K USD
KCK LTD.
10 percent owner
- 2504
6.117 USD
3 months ago
Oct 11, 2024
Sell 16.3 K USD
KCK LTD.
10 percent owner
- 2572
6.3451 USD
3 months ago
Oct 14, 2024
Sell 26.4 K USD
KCK LTD.
10 percent owner
- 4031
6.5393 USD
3 months ago
Oct 15, 2024
Sell 26.1 K USD
KCK LTD.
10 percent owner
- 4017
6.497 USD
3 months ago
Oct 16, 2024
Sell 45.3 K USD
KCK LTD.
10 percent owner
- 6900
6.5705 USD
3 months ago
Oct 17, 2024
Sell 20.7 K USD
KCK LTD.
10 percent owner
- 3294
6.28 USD
4 months ago
Aug 30, 2024
Sell 33.5 K USD
KCK LTD.
10 percent owner
- 4314
7.76 USD
4 months ago
Sep 03, 2024
Sell 15.9 K USD
KCK LTD.
10 percent owner
- 2093
7.6 USD
4 months ago
Sep 04, 2024
Sell 105 USD
KCK LTD.
10 percent owner
- 14
7.5 USD
4 months ago
Sep 06, 2024
Sell 82.5 USD
KCK LTD.
10 percent owner
- 11
7.5 USD
4 months ago
Sep 13, 2024
Sell 15.1 K USD
KCK LTD.
10 percent owner
- 1993
7.59 USD
3 months ago
Sep 20, 2024
Sell 5.74 K USD
KCK LTD.
10 percent owner
- 765
7.5 USD
3 months ago
Sep 23, 2024
Sell 2.13 K USD
KCK LTD.
10 percent owner
- 282
7.54 USD
3 months ago
Sep 25, 2024
Sell 38.7 K USD
KCK LTD.
10 percent owner
- 5858
6.6 USD
3 months ago
Sep 26, 2024
Sell 38.5 K USD
KCK LTD.
10 percent owner
- 5821
6.62 USD
3 months ago
Sep 27, 2024
Sell 33.5 K USD
KCK LTD.
10 percent owner
- 5059
6.63 USD
3 months ago
Sep 30, 2024
Sell 32 K USD
KCK LTD.
10 percent owner
- 4749
6.73 USD
3 months ago
Oct 01, 2024
Sell 33.1 K USD
KCK LTD.
10 percent owner
- 4882
6.77 USD
3 months ago
Oct 02, 2024
Sell 26.4 K USD
KCK LTD.
10 percent owner
- 3843
6.87 USD
8 months ago
May 01, 2024
Sell 220 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 15690
14.02 USD
8 months ago
May 02, 2024
Sell 124 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 8842
14.01 USD
8 months ago
May 03, 2024
Sell 65.6 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 4674
14.03 USD
8 months ago
Apr 24, 2024
Sell 25 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 1781
14.06 USD
9 months ago
Apr 19, 2024
Sell 256 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 18253
14.02 USD
8 months ago
Apr 22, 2024
Sell 346 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 24609
14.05 USD
8 months ago
Apr 23, 2024
Sell 311 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 21791
14.29 USD
9 months ago
Apr 16, 2024
Sell 197 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 14069
14.01 USD
9 months ago
Apr 17, 2024
Sell 4.24 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 300
14.15 USD
9 months ago
Apr 18, 2024
Sell 36.9 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 2623
14.06 USD
9 months ago
Apr 11, 2024
Sell 6.69 M USD
ORBIMED ADVISORS LLC
10 percent owner
- 461899
14.49 USD
9 months ago
Apr 12, 2024
Sell 333 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 23101
14.42 USD
11 months ago
Feb 02, 2024
Sell 213 K USD
Morrell Martha
Chief Medical Officer
- 14143
15.0691 USD
11 months ago
Feb 05, 2024
Sell 52.3 K USD
Morrell Martha
Chief Medical Officer
- 3446
15.1707 USD
11 months ago
Jan 30, 2024
Sell 170 K USD
Morrell Martha
Chief Medical Officer
- 11262
15.0954 USD
11 months ago
Jan 31, 2024
Sell 29 K USD
Morrell Martha
Chief Medical Officer
- 1923
15.0752 USD
11 months ago
Feb 01, 2024
Sell 9.97 K USD
Morrell Martha
Chief Medical Officer
- 663
15.0393 USD
11 months ago
Jan 24, 2024
Sell 12.4 K USD
Morrell Martha
Chief Medical Officer
- 827
15.025 USD
11 months ago
Jan 25, 2024
Sell 15 USD
Morrell Martha
Chief Medical Officer
- 1
15 USD
1 year ago
Dec 26, 2023
Sell 1.02 K USD
Morrell Martha
Chief Medical Officer
- 102
10 USD
1 year ago
Dec 27, 2023
Sell 135 K USD
Morrell Martha
Chief Medical Officer
- 13300
10.1239 USD
1 year ago
Dec 20, 2023
Sell 27.7 K USD
Morrell Martha
Chief Medical Officer
- 2730
10.1448 USD
1 year ago
Dec 06, 2023
Sell 89.8 K USD
Morrell Martha
Chief Medical Officer
- 11005
8.1575 USD
1 year ago
Nov 29, 2023
Sell 49.2 K USD
KCK LTD.
10 percent owner
- 5644
8.72 USD
1 year ago
Nov 30, 2023
Sell 64.4 K USD
KCK LTD.
10 percent owner
- 7282
8.84 USD
1 year ago
Dec 01, 2023
Sell 28.3 K USD
KCK LTD.
10 percent owner
- 3241
8.73 USD
1 year ago
Nov 27, 2023
Sell 58.2 K USD
KCK LTD.
10 percent owner
- 6490
8.96 USD
1 year ago
Nov 28, 2023
Sell 41 K USD
KCK LTD.
10 percent owner
- 4681
8.75 USD
1 year ago
Oct 02, 2023
Sell 69.1 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 7614
9.08 USD
1 year ago
Oct 03, 2023
Sell 6.31 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 700
9.02 USD
2 years ago
Nov 22, 2022
Bought 93.5 K USD
Accelmed Partners II L.P.
Director
+ 62398
1.499 USD
2 years ago
Nov 21, 2022
Bought 492 K USD
Accelmed Partners II L.P.
Director
+ 327893
1.499 USD
2 years ago
Jun 08, 2022
Sell 14.4 K USD
Ridley Irina
General Counsel and Secretary
- 2500
5.778 USD
2 years ago
Feb 28, 2022
Sell 11.1 K USD
Ridley Irina
General Counsel and Secretary
- 1470
7.5386 USD
3 years ago
Apr 21, 2021
Bought 4 M USD
ORBIMED ADVISORS LLC
10 percent owner
+ 235000
17 USD
3 years ago
Apr 21, 2021
Bought 40 K USD
Ridley Irina
General Counsel and Secretary
+ 2352
17 USD
3 years ago
Apr 21, 2021
Bought 10 M USD
Accelmed Partners II L.P.
10 percent owner
+ 588235
17 USD
3 years ago
Apr 21, 2021
Bought 850 K USD
Fischer Frank M
Director
+ 50000
17 USD
3 years ago
Apr 21, 2021
Bought 225 K USD
Garfield Greg Shaw
Director
+ 13235
17 USD
3 years ago
Apr 21, 2021
Bought 10 M USD
Norton Evan
Director
+ 588235
17 USD
7. News
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 3 weeks ago
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference. globenewswire.com - 1 month ago
NeuroPace to Host Investor Day on January 28th in New York City MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City. globenewswire.com - 1 month ago
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 1 month ago
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatment experience for physicians and patients NeuroPace's Booth #2119 MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 2024 American Epilepsy Society Annual Meeting (AES 2024). globenewswire.com - 1 month ago
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy globenewswire.com - 1 month ago
What Makes NeuroPace (NPCE) a New Buy Stock NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 months ago
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade The mean of analysts' price targets for NeuroPace (NPCE) points to a 54.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2 months ago
NeuroPace, Inc. (NPCE) Q3 2024 Earnings Call Transcript NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael Polark – Wolfe Research Operator Greetings and welcome to NeuroPace's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.28 per share a year ago. zacks.com - 2 months ago
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy globenewswire.com - 2 months ago
Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? NeuroPace (NPCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 2 months ago
8. Profile Summary

NeuroPace, Inc. NPCE

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 357 M
Dividend Yield 0.00%
Description NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Contact 455 North Bernardo Avenue, Mountain View, CA, 94043 https://www.neuropace.com
IPO Date April 22, 2021
Employees 184
Officers Ms. Leah Akin General Counsel & Corporate Secretary Dr. Martha J. Morrell M.D. Chief Medical Officer Ms. Kelley Nicholas Vice President of Sales Ms. Rebecca L. Kuhn Chief Financial Officer, Vice President of Finance & Administration Ms. Amy Treadwell Vice President of Human Resources Mr. Joel D. Becker Chief Executive Officer, President & Director Mr. Dylan St. John Chief of Operations & Development